Agree DB that if DXB technology is proven in current trials then it will have more potential than RAP. For the record I hold RAP, I'm not dissing it in any way, I still think it is good value. But DXB and RAP are completely different. Different markets, different technology, different research demands, different revenues. I'm not sure there is a reasonable comparison to make. They aren't similar in any way, for me at least.
We just need to await further trial results here. Whilst the kidney application has its own market which is valuable stand alone, the kidney trial is also important because it serves as a demonstration of the broader discovery platform. For kidney I agree with the presentation that even a small number of responders is a good result.
Agree DB that if DXB technology is proven in current trials then...
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.5¢ |
Change
-0.015(3.19%) |
Mkt cap ! $250.3M | |||
| Open | High | Low | Value | Volume |
| 46.5¢ | 49.0¢ | 45.5¢ | $1.515M | 3.232M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 161532 | 45.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 46.5¢ | 33998 | 2 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |